Treatment of lung cancer

Abstract

Disclosed are methods of treating lung cancer by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with a chemotherapeutic agent. Chemotherapeutic agents, and combinations thereof, for use with FTS, its analogs, or its salts are also disclosed.

1 . A method of treating a human afflicted with lung cancer, comprising administering to the human an effective amount of FTS or an analog thereof as represented by the formula: 
       
         
           
           
               
               
           
         
       
       wherein
 R 1  represents farnesyl or geranyl-geranyl; 
 R 2  represents the groups COOR 7 , CONR 7 R 8 , wherein R 7  and R 8  are each independently hydrogen, alkyl or alkenyl, and COOM wherein 
 M is a cation; 
 R 3 , R 4 , R 5  and R 6  are each independently hydrogen, alkyl, alkenyl, alkoxy, halo, trifluoromethyl, trifluoromethoxy, or alkylmercapto; and 
 X represents S; or a pharmaceutically acceptable salt thereof, and 
 a chemotherapeutic agent. 
 
     
     
         2 . The method of  claim 1 , wherein the human afflicted with lung cancer is administered FTS. 
     
     
         3 . The method of  claim 1 , wherein the human afflicted with lung cancer is administered an analog of FTS which is GGTS. 
     
     
         4 . The method of  claim 1 , wherein FTS or its analog or a pharmaceutically acceptable salt thereof is administered orally. 
     
     
         5 . The method of  claim 1 , wherein the chemotherapeutic agent is administered intravenously. 
     
     
         6 . The method of  claim 1 , wherein the chemotherapeutic agent is vinorelbine. 
     
     
         7 . The method of  claim 1 , wherein the chemotherapeutic agent is doxorubicin. 
     
     
         8 . The method of  claim 1 , wherein the chemotherapeutic agent is paclitaxel. 
     
     
         9 . The method of  claim 1 , wherein the chemotherapeutic agent is docetaxel. 
     
     
         10 . The method of  claim 1 , wherein the chemotherapeutic agent is a platinum based drug or an analog thereof. 
     
     
         11 . The method of  claim 10 , wherein the platinum based drug is cisplatin. 
     
     
         12 . The method of  claim 10 , wherein the platinum based drug is carboplatin. 
     
     
         13 . The method of  claim 1 , wherein the chemotherapeutic agent is pemetrexed. 
     
     
         14 . The method of  claim 1 , wherein the chemotherapeutic agent is doxorubicin. 
     
     
         15 . The method of  claim 1 , wherein the chemotherapeutic agent is etoposide. 
     
     
         16 . The method of  claim 1 , wherein the chemotherapeutic agent is topotecan. 
     
     
         17 . The method of  claim 1 , wherein the chemotherapeutic agent is vinblastine. 
     
     
         18 . The method of  claim 1 , wherein the chemotherapeutic agent is vindesine. 
     
     
         19 . The method of  claim 1 , wherein the chemotherapeutic agent is ifosfamide. 
     
     
         20 . The method of  claim 1 , wherein the chemotherapeutic agent is mitomycin.